|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Herpes zoster infections: Aciclovir is indicated for the acute treatment of herpes zoster (shingles). Genital herpes: Aciclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Aciclovir is indicated for the treatment of chickenpox (varicella).
Aciclovir is contraindicated for patients who develop hypersensitivity to Aciclovir or Valaciclovir.
Herpes simplex: Short term administration: the most frequent adverse events reported with Aciclovir 200 mg administered orally 5 times daily every 4 hours for 10 days were nausea and/or vomiting. Long term administration: the most frequent adverse events reported in a clinical trial for the prevention of recurrences with continuous administration of 400 mg 2 times daily for 1 year were nausea (4.8%) and diarrhea (2.4%). Herpes zoster: the most frequent adverse event reported with 800 mg of oral Aciclovir 5 times daily for 7 to 10 days in 323 patients was malaise (11.5%). Chickenpox: the most frequent adverse event reported with oral Aciclovir at doses of 10 to 20 mg/kg 4 times daily for 5 to 7 days was diarrhea (3.2%). Observed during clinical practice: in addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of Aciclovir. General: anaphylaxis, angioedema, fever, headache, pain, peripheral edema. Nervous: aggressive behavior, agitation, ataxia, coma, confusion, decreased consciousness, delirium, dizziness, encephalopathy, hallucinations, paresthesia, psychosis, seizure, somnolence, tremors. These symptoms may be marked, particularly in older adults or in patients with renal impairment. Digestive: diarrhea, gastrointestinal distress, nausea. Hematologic and lymphatic: anemia, leukocytoclastic vasculitis, leukopenia, lymphadenopathy, thrombocytopenia. Hepatobiliary tract and pancreas: elevated liver function tests, hepatitis, hyperbilirubinemia, jaundice. Musculoskeletal: myalgia. Skin: alopecia, erythema multiforme, photosensitive rash, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria. Skin: alopecia, erythema multiforme, photosensitive rash, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria. Urogenital: renal failure, elevated blood urea nitrogen, elevated creatinine, hematuria.
Drug Interactions: coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced.
dosage adjustment is recommended when administering Aciclovir to patients with renal impairment. Caution should also be exercised when administering Aciclovir to patients receiving potentially nephrotoxic agents since this may increase the risk of renal dysfunction and/or the risk of reversible central nervous system symptoms such as those that have been reported in patients treated with intravenous Aciclovir. Information for Patients: patients are instructed to consult with their physician if they experience severe or troublesome adverse reactions, they become pregnant or intend to become pregnant, they intend to breastfeed while taking orally administered Aciclovir or they have any other questions. Herpes zoster: there are no data on treatment initiated more than 72 hours after onset of the zoster rash. Genital herpes infections: patients should be informed that Aciclovir is not a cure for genital herpes. Chickenpox: adolescents and adults tend to have more severe disease. Treatment was initiated within 24 hours of the typical chickenpox rash. Pregnancy: Pregnancy Category B. Nursing Mothers: Aciclovir should be administered to a nursing mother with caution and only when indicated. Pediatric Use: safety and effectiveness of oral formulations of Aciclovir in pediatric patients less than 2 years of age have not been established. Geriatric Use: elderly patients are more likely to have reduced renal function and require dose reduction. Elderly patients are also more likely to have renal or CNS adverse events.
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Dr . Dirar Abboud
Dr. Samer Al-Jneidy
Yaser Habrawi , F.R.C.S.Ed
Dr. Faisal Dibsi
Samir Moussa M.D.
Dr. Talal Sabouni
Dr. Hani Najjar
Dr. Tahsin Martini